DexCom is a high-quality franchise with a wide economic moat, best-in-class margins, and four consecutive earnings beats, but the stock's current price leaves only 3.3% upside to the analyst target; the thesis favors a patient entry near $64 rather than initiating at current levels where the near-term risk/reward does not clear the minimum bar.
Thesis pillars
- Wide Economic Moat And Compounder Quality→Stable
- Thin Upside At Current Price Level↓Deteriorating
- Four Consecutive Earnings Beats↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 12, 2026
DexCom, Inc. (DXCM) Stock Analysis
Healthcare · Medical Devices
Wait for pullback to $76.49. Weak momentum — blocks BUY_NOW at $78.62. Engine's entry $76.49 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers.
DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with products including the G7, G7 15 Day, and the Stelo OTC biosensor sold globally. Revenue comes primarily from CGM system sales through third-party payors... Read more
Wait for pullback to $76.49. Weak momentum — blocks BUY_NOW at $78.62. Engine's entry $76.49 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers. Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Score 6.7/10, high confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — DexCom, Inc.
Latest news
- NEWS DXCM261120C00070000 Interactive Stock Chart | DXCM Nov 2026 70.000 call Stock - Yahoo Finance — Yahoo Finance neutral
- NEWS DexCom (DXCM) Could Be 12% Undervalued Following Its Rebound - Yahoo Finance — Yahoo Finance positive
- NEWS DexCom (DXCM) Could Be 12% Undervalued Following Its Rebound - finance.yahoo.com — finance.yahoo.com positive
- NEWS DexCom (DXCM) Could Be 12% Undervalued Following Its Rebound - Yahoo Finance Singapore — Yahoo Finance Singapore positive
- NEWS DXCM|Dexcom Inc|Price:74.830|Chg%:+1.460 - TradingKey — TradingKey neutral
Generated 2026-10-29T11:48:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCGM systems10-K Item 1A: 'sales of our CGM systems will account for substantially all of our product revenue for the foreseeable future'
- HIGHSuppliersingle- or sole-source suppliers10-K Item 1A: 'our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $76.49. Weak momentum — blocks BUY_NOW at $78.62. Engine's entry $76.49 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers. Chart setup: No clear chart pattern; technical signals are mixed. Earnings today. Wait until post-earnings. Target $86.57 (+10.1%), stop $71.19 (−10.4%), A.R:R 1.5:1. Score 6.7/10, high confidence.
Take-profit target: $86.57 (+10.1% upside). Target $86.57 (+10.1%), stop $71.19 (−10.4%), A.R:R 1.5:1. Stop-loss: $71.19.
Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers.
DexCom, Inc. trades at a P/E of 31.2 (forward 25.2). TrendMatrix value score: 4.7/10. Verdict: Buy (Wait for Entry).
35 analysts cover DXCM with a consensus score of 4.3/5. Average price target: $96.
What does DexCom, Inc. do?DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with...
DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with products including the G7, G7 15 Day, and the Stelo OTC biosensor sold globally. Revenue comes primarily from CGM system sales through third-party payors including Medicare, Medicaid, and commercial insurers, with the G7 covered in the majority of states. The G7 15 Day received FDA marketing authorization in April 2025 and is the most accurate CGM cleared by the FDA.